

## Disclosures

### Personal Commercial (7)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen Inc.	Research/Research Grants	None (\$0)	<i>Stable Ischemic Heart Disease</i>
GE Healthcare	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Noninvasive Imaging</i>
Gilead Sciences, Inc.	Research/Research Grants ‡ Effects of Bictegravir-Emtricitabine-Tenofovir Alafenamide on Coronary Flow Reserve	Significant (>= \$5,000)	<i>Other</i>
MedTrace	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Noninvasive Imaging</i>
SOFIE	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Noninvasive Imaging</i>
Sun Pharma	Research/Research Grants ‡ Effects of Tildrakizumab on Coronary Microvascular Function in Moderate-Severe Psoriasis	Significant (>= \$5,000)	<i>Prevention</i>
Valo Health	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Stable Ischemic Heart Disease</i>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (2)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
National Institutes of Health	Research/Research Grants	Significant (>= \$5,000)	<i>Stable Ischemic Heart Disease</i>
NHLBI T32HL094301	Research/Research Grants	Significant (>= \$5,000)	<i>Noninvasive Imaging</i>

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 9/22/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 9/22/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 9/22/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

### On-Going Obligation Agreement | Signed on 9/22/2025

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.